Antisense Oligonucleotides for JC Virus Inhibition
Solution Overview
Problem
Current therapies for progressive multifocal leukoencephalopathy (PML) are ineffective due to nonspecific side effects and limited ability to target JC virus replication, with existing drugs disrupting both viral and cellular DNA synthesis, and RNAi agents lacking stability and specificity.
Innovation Solution
Development of a library of antisense oligodeoxynucleotides (ODNs) specifically designed to target and inhibit JC virus replication by binding to nucleic acid sequences within the JC virus genome, incorporating phosphorothioate backbone modifications and 2' sugar modifications for increased stability and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogs are used to inhibit JCV replication, then viral DNA synthesis is disrupted, but cellular DNA synthesis of host is also disrupted causing severe side effects
Solution Approach 1:
The invention segments the target into two distinct components: viral DNA polymerase and host cellular DNA polymerase. By designing antisense oligonucleotides that specifically hybridize to viral DNA sequences, the treatment selectively inhibits viral replication without affecting host cellular DNA synthesis, thereby resolving the contradiction between effective viral inhibition and host safety
Solution Approach 2:
The antisense oligonucleotide acts as an intermediary molecule that binds specifically to viral DNA sequences, blocking viral replication through sequence-specific hybridization. This intermediary approach allows selective targeting of viral DNA without direct interaction with or inhibition of host DNA polymerase, eliminating the harmful side effects while maintaining effective antiviral activity
2Reliability
If receptor antagonists are used to block JCV entry, then viral infection is inhibited, but other receptor functions are blocked causing nonspecific side effects and toxicity
Solution Approach 1:
The invention segments the therapeutic approach by shifting from broad-spectrum receptor antagonism to highly specific sequence-targeted inhibition. Antisense oligonucleotides are designed to hybridize exclusively with specific viral DNA sequences, creating a segmented and selective mechanism that avoids nonspecific receptor blockade and its associated side effects
Solution Approach 2:
The therapeutic agent exhibits local quality through sequence-specific binding. The antisense oligonucleotides are engineered with specific nucleotide sequences that complement and bind only to corresponding viral DNA regions, creating localized and precise inhibition at the molecular level while leaving other cellular processes unaffected
3Reliability
If RNAi agents are used to reduce JCV replication, then viral replication is suppressed, but the agents lack stability and specificity for in vivo therapeutic use
Solution Approach 1:
The invention applies parameter changes by modifying the chemical structure of oligonucleotide backbones and incorporating stabilizing modifications. These parameter changes enhance nuclease resistance, improve pharmacokinetic properties, and maintain sequence-specific binding affinity, thereby achieving both stability and specificity required for effective in vivo therapeutic application
Solution Approach 2:
The antisense oligonucleotide constructs function as composite molecular materials combining sequence-specific RNA/DNA binding capability with enhanced chemical stability. The design integrates specific nucleotide sequences with stabilizing chemical modifications, creating a composite agent that maintains both target specificity and in vivo stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense ODNs effectively reduce JC virus replication and multiplication, demonstrating high biological activity and stability in vitro, with potential for therapeutic use in treating PML by selectively silencing JC virus genes without significant cytotoxicity.
Implementation Method 1
antisense oligonucleotide which is targeted to a nucleic acid encoding polyomavirus JC (JCV), and is capable of inhibiting JCV replication and multiplication
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The instant invention provides compositions and methods for inhibiting the JC Virus (JCV), and that can be used, for example, for treating progressive multifocal leukoencephalopathy (PML). Antisense oligonucleotides are provided which are effective in inhibiting JCV replication or multiplication, alone or in a combination. In preferred embodiments, the oligonucleotides contain modifications.